Literature DB >> 21613432

Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic.

Pankaj Srivastava1, Vijay Kumar Prajapati, Madhukar Rai, Shyam Sundar.   

Abstract

The case of a patient with visceral leishmaniasis showing inadequate response to amphotericin B from a region where leishmaniasis is not endemic is reported, with the Leishmania donovani isolate showing increased tolerance to amphotericin B in vivo. Four single nucleotide polymorphisms (SNPs) detected in the cysteine proteinase B gene resulted in changes to the deduced amino acid sequence: valine→alanine and arginine→leucine. Overexpression and underexpression of proteins were observed in the 65- to 80-kDa range and at 20 kDa, respectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613432      PMCID: PMC3146580          DOI: 10.1128/JCM.00173-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.

Authors:  S Sundar; D K More; M K Singh; V P Singh; S Sharma; A Makharia; P C Kumar; H W Murray
Journal:  Clin Infect Dis       Date:  2000-10       Impact factor: 9.079

2.  Gene amplification in amphotericin B-resistant Leishmania tarentolae.

Authors:  A K Singh; B Papadopoulou; M Ouellette
Journal:  Exp Parasitol       Date:  2001-11       Impact factor: 2.011

3.  Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India.

Authors:  Paul G Barnett; S P Singh; Caryn Bern; Allen W Hightower; Shyam Sundar
Journal:  Am J Trop Med Hyg       Date:  2005-10       Impact factor: 2.345

Review 4.  Amphotericin B: spectrum and resistance.

Authors:  David Ellis
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

5.  Antileishmanial activity of nano-amphotericin B deoxycholate.

Authors:  Krishna Das Manandhar; Thakur Prasad Yadav; Vijay Kumar Prajapati; Subodh Kumar; Madhukar Rai; Anuradha Dube; Onkar Nath Srivastava; Shyam Sundar
Journal:  J Antimicrob Chemother       Date:  2008-05-02       Impact factor: 5.790

6.  A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.

Authors:  V Yardley; S L Croft
Journal:  Int J Antimicrob Agents       Date:  2000-02       Impact factor: 5.283

7.  Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes.

Authors:  Vijay Kumar Prajapati; Kalpana Awasthi; Shalini Gautam; Thakur Prasad Yadav; Madhukar Rai; Onkar Nath Srivastava; Shyam Sundar
Journal:  J Antimicrob Chemother       Date:  2011-02-03       Impact factor: 5.790

8.  Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.

Authors:  Laurence Lachaud; Nathalie Bourgeois; Marie Plourde; Philippe Leprohon; Patrick Bastien; Marc Ouellette
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

9.  Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase B and surface metalloprotease glycoprotein 63 in the Leishmania donovani complex.

Authors:  Kelly Wilber Quispe Tintaya; Xu Ying; Jean-Pierre Dedet; Suman Rijal; Xavier De Bolle; Jean-Claude Dujardin
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

10.  First case of indigenous visceral leishmaniasis from central India.

Authors:  Ayan Dey; Umakant Sharma; Sarman Singh
Journal:  Am J Trop Med Hyg       Date:  2007-07       Impact factor: 2.345

  10 in total
  22 in total

1.  Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani.

Authors:  Bidyut Purkait; Ashish Kumar; Nilay Nandi; Abul Hasan Sardar; Sushmita Das; Sudeep Kumar; Krishna Pandey; Vidyananda Ravidas; Manish Kumar; Tripti De; Dharmendra Singh; Pradeep Das
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

Review 2.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

Review 3.  Molecular Diagnosis of Visceral Leishmaniasis.

Authors:  Shyam Sundar; Om Prakash Singh
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

4.  Amphotericin B resistance in Leishmania mexicana: Alterations to sterol metabolism and oxidative stress response.

Authors:  Edubiel A Alpizar-Sosa; Nur Raihana Binti Ithnin; Wenbin Wei; Andrew W Pountain; Stefan K Weidt; Anne M Donachie; Ryan Ritchie; Emily A Dickie; Richard J S Burchmore; Paul W Denny; Michael P Barrett
Journal:  PLoS Negl Trop Dis       Date:  2022-09-28

5.  A novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts.

Authors:  Gerhard Bringmann; Katja Thomale; Sebastian Bischof; Christoph Schneider; Martina Schultheis; Tobias Schwarz; Heidrun Moll; Uta Schurigt
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

6.  In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugs.

Authors:  Vijay Kumar Prajapati; Sanjana Mehrotra; Shalini Gautam; Madhukar Rai; Shyam Sundar
Journal:  Am J Trop Med Hyg       Date:  2012-08-27       Impact factor: 2.345

Review 7.  The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities?

Authors:  Mayilsamy Muniaraj
Journal:  Trop Parasitol       Date:  2014-01

Review 8.  Comparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmania.

Authors:  Gagandeep Kaur; Bhawana Rajput
Journal:  J Parasitol Res       Date:  2014-05-12

9.  Immunobiology of visceral leishmaniasis.

Authors:  Rajiv Kumar; Susanne Nylén
Journal:  Front Immunol       Date:  2012-08-14       Impact factor: 7.561

10.  Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection.

Authors:  Sandip Mukherjee; Budhaditya Mukherjee; Rupkatha Mukhopadhyay; Kshudiram Naskar; Shyam Sundar; Jean Claude Dujardin; Anjan Kumar Das; Syamal Roy
Journal:  PLoS Negl Trop Dis       Date:  2012-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.